SCHEMBL3142160

SCHEMBL3142160

Nc1ccc(Oc2ccc(CCC(=O)N3CCN(Cc4ccc5c(c4)OCO5)CC3)cc2)nc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.55
KMT2A Q03164 8/20 0.55
MEN1 O00255 7/20 0.55
MAPT P10636 3/20 0.55
CYP3A4 P08684 2/20 0.55
POLB P06746 2/20 0.55
ABCB11 O95342 1/20 0.55
CYP1A2 P05177 1/20 0.55
ADRA2A P08913 1/20 0.55
CYP2D6 P10635 1/20 0.55
CHRM1 P11229 1/20 0.55
TBXA2R P21731 1/20 0.55
SLC6A2 P23975 1/20 0.55
SLC6A4 P31645 1/20 0.55
CYP2C19 P33261 1/20 0.55
ADRA1A P35348 1/20 0.55
OPRM1 P35372 1/20 0.55
DRD3 P35462 1/20 0.55
SLC6A3 Q01959 1/20 0.55
KCNH2 Q12809 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3134931 0.99 CYP3A4 (0.56) LMNAKMT2AMEN1MAPTCYP3A4
SCHEMBL3134806 0.90 KMT2A (0.65) LMNAKMT2AMEN1MAPTCYP3A4
SCHEMBL4761617 0.89 LMNA (0.54) LMNAKMT2AMEN1MAPTCYP3A4
SCHEMBL3143101 0.89 LMNA (0.54) LMNAKMT2AMEN1MAPTCYP3A4
SCHEMBL8952639 0.88 KMT2A (0.56) LMNAKMT2AMEN1MAPTCYP3A4
SCHEMBL3133426 0.87 LMNA (0.58) LMNAKMT2AMEN1MAPTCYP3A4
SCHEMBL4761618 0.87 LMNA (0.50) LMNAKMT2AMEN1MAPTCYP3A4
SCHEMBL11981248 0.87 KMT2A (0.56) LMNAKMT2AMEN1MAPTCYP3A4
SCHEMBL14496805 0.86 MEN1 (0.54) LMNAKMT2AMEN1MAPTCYP3A4
SCHEMBL5248151 0.85 FAAH (0.53) LMNAKMT2AMEN1MAPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1957073-B1 MEDICINAL DRUG OTSUKA PHARMA CO LTD (JP) 2014-04-23 EP disclosed
US-20120238750-A1 AROMATIC COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2012-09-20 US disclosed
US-8236826-B2 Diarylether derivatives as antitumor agents OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-08-07 US disclosed
US-8188277-B2 Aromatic compounds for suppressing the generation of collagen OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-05-29 US disclosed
US-20100004438-A1 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-01-07 US disclosed
US-20070270422-A1 Aromatic Compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238750-A1 AROMATIC COMPOUND CBR1, CBR3, CYP1A1 LMNA 2721/4885KMT2A 984/4885MEN1 1020/4885
US-20100004438-A1 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS ROS1, CBR1, CBR3 LMNA 4340/4885KMT2A 1623/4885MEN1 1851/4885
US-20070270422-A1 Aromatic Compounds COL1A1, COL2A1, COL14A1 LMNA 1091/4885KMT2A 2349/4885MEN1 3512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.